Next-Generation Sequencing (NGS) Diagnostics Market - Strategic Insights and Forecasts (2026-2031)

The Next-Generation Sequencing (NGS) Diagnostics Market is forecast to reach USD 44.8 billion by 2031, growing from USD 24.0 billion in 2026. This represents a robust Compound Annual Growth Rate (CAGR) of 13.3% over the forecast period, as detailed in the "Next-generation Sequencing (NGS) Diagnostics Market - Strategic Insights and Forecasts (2026-2031)" report.

The market is primarily driven by the increasing demand for thorough tumour profiling in oncology, expanding hereditary disease screening for rare genetic conditions, and the integration of NGS into infectious pathogen surveillance programs. NGS also plays a role in screening during pregnancy, collectively enhancing precision diagnostics across these critical applications.

Key drivers include the rising incidence of cancer and hereditary diseases, which increases the demand for comprehensive genomic information to inform diagnosis and treatment. Strategic trends also involve the establishment of regulatory frameworks by agencies like the FDA and WHO, alongside significant technological advances in bioinformatics and data analysis tools.

Public health agencies and regulators, such as the U.S. FDA, are establishing frameworks and guidelines for the oversight of genomic tests and software to ensure their analytical validity and clinical utility. The World Health Organization (WHO) is also collaborating with public health bodies to advance genomic surveillance for infectious diseases and monitor antimicrobial resistance.

The report emphasizes significant technological advances in bioinformatics and data analysis as crucial for the market's future. This includes the availability of more sophisticated analytical software and artificial intelligence tools, which are essential for efficiently processing, analyzing, and interpreting the vast amounts of genomic data generated by NGS platforms.

The report highlights NGS as a key technology for precision diagnostics due to its ability to assess many genes simultaneously, solidifying genomics' role in everyday oncology practice through widespread tumour profiling. It also details improved preventive strategies via hereditary disease screening and more efficient infectious disease outbreak tracking, all supported by evolving regulatory frameworks for integration into precision medicine.